A number of cancer vaccine strategies have entered initial Phase I clinical
testing. In this review, Dr. Glenn Dranoff discusses the prospects that ap
propriate immunologic monitoring of patients in these trials can help delin
eate important differences among the various immunization strategies and pr
ioritize the most promising approaches for further clinical development. Co
pyright (C) 1999 John Wiley & Sons, Ltd.